GlassScriptPhysician profile
Kelly L Sprout
NPI 1659422129
$5,210.24
in general payments reported to CMS, 2019-2025
18 companies · $1,186 in 2025
The $1,186 reported for 2025 was more than what 83% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $663 · 2020: $98.76 · 2021: $455 · 2022: $468 · 2023: $1,109 · 2024: $1,230 · 2025: $1,186.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,414 · Education: $111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,413.66 |
| Education | $111.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $869.73 | 2021-2025 | Vraylar |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $851.12 | 2021-2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $765.06 | 2019-2025 | Invega Sustenna, Invega Trinza, Spravato |
| Teva Pharmaceuticals USA, INC. | $620.63 | 2022-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Otsuka America Pharmaceutical, INC. | $468.64 | 2019-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Indivior INC. | $353.98 | 2019-2024 | Perseris, Sublocade |
| Alkermes, INC. | $349.37 | 2019-2025 | Aristada, Lybalvi |
| Lundbeck LLC | $232.99 | 2019-2025 | Rexulti |
| Neurocrine Biosciences, INC. | $157.89 | 2019-2025 | Ingrezza |
| E.R. Squibb & Sons, L.L.C. | $142.90 | 2025 | Cobenfy |
| Takeda Pharmaceuticals U.S.A., INC. | $134.97 | 2019-2024 | Trintellix, Vyvanse |
| Vanda Pharmaceuticals INC. | $93.70 | 2019 | |
| Axsome Therapeutics, INC. | $85.16 | 2023-2025 | Auvelity |
| Allergan, INC. | $40.90 | 2019-2020 | |
| Idorsia Pharmaceuticals US INC | $13.77 | 2022 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sage Therapeutics, LLC | $13.65 | 2024 | |
| Shire North American Group INC | $13.27 | 2019 | |
| Validus Pharmaceuticals LLC | $2.51 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kelly Sprout listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.